Invited for debate: is virus persistence a determinant for disease progression?

Area of Science:

• Cardiology
• Virology
• Immunology

Background:

• Viruses can infect and damage the heart muscle (myocardium), leading to chronic heart conditions.
• The precise role of detected viruses in endomyocardial biopsies and their prognostic impact remains unclear.
• Existing clinical data on viral cardiomyopathy prognosis is inconsistent, necessitating robust randomized trials.

Purpose of the Study:

• To evaluate the efficacy of antiviral therapy in patients with inflammatory cardiomyopathy and myocardial viral genomes.
• To provide evidence-based insights into the management of viral cardiomyopathy.
• To assess the potential of targeted antiviral treatment to prevent disease progression and reverse cardiac damage.

Main Methods:

• The Betaferon in Chronic Viral Cardiomyopathy (BICC) study is a large-scale, randomized clinical trial.
• Patients with inflammatory cardiomyopathy and detectable viral genomes in myocardial tissue are enrolled.
• The trial assesses the impact of a specific antiviral therapy.

Main Results:

• The BICC trial is currently ongoing and has not yet reported results.
• Anticipated results will clarify the pathogenetic role of myocardial viruses.
• The study aims to determine if antiviral therapy can improve myocardial function and reduce damage.

Conclusions:

• The BICC trial is expected to yield crucial scientific evidence regarding antiviral therapy for viral cardiomyopathy.
• Results may support the clinical application of targeted antiviral treatments.
• This research could significantly impact the prevention and management of myocardial dysfunction caused by viral infections.